Chris Tyler

Chris Tyler

Chris Tyler, a Wall Street veteran of more than 20 years, began his career in the financial markets working on the trading floor of the AMEX in New York as an equity option market maker at Interactive Brokers’ floor trading unit Timber Hill LLC.

After moving to San Francisco to make markets on the P-Coast exchange during the dot-com craze and spending nearly a decade working in names like Philip Morris, Seagate and Compaq, Chris hung up his smock and trading badge, but not his passion for options and the markets.

Since exiting the floor, and for the better part of the past dozen years, Chris has worked as an option and market strategist, writing analyses for Trading Markets, Charles Schwab subsidiary Optionetics and as a featured columnist at Investor’s Business Daily.

Aside from offering his trading insights at InvestorPlace.com, Chris is currently studying for his Accredited Portfolio Management Advisor (APMA) designation, manages investments for closely held accounts and offers his services as an investment strategist to GLJ Advisors, a CA based RIA.

Chris, his wife and blue heeler live in the Pacific NW. And if you can’t follow him around in your own VW Vanagon or Westfalia, feel free to follow him on Twitter via @Options_CAT.

Recent Articles

Warts and All, Here’s Why JFrog Stock Is a Buy

Let’s just say better-than-expected earnings failed to impress investors, but FROG stock may yet turn into a princely investment

3 Well-Discounted Covid-19 Stocks to Buy

Positive Covid-19 vaccine reports may have taken these companies' shares lower, but now more than ever they’re stocks to buy.

Why Carnival Is Still Stuck on the List of Stocks to Avoid

If you’re going to book a trip in CCL stock despite today’s headwinds, "travel insurance" through Carnival’s options market is mandatory.

Investors Find the Right Rx With Teladoc Stock

Bad news for the coronavirus has spelled short-term trouble for Teladoc stock, but longer-term opportunity for tomorrow’s investors.

3 ‘Stay Away’ Stocks to Buy Today

Exposure to Covid-19 is risky business, but promising drug results and deeply-discounted price action set up three stocks to buy